Previous 10 | Next 10 |
No severe adverse events reported to date Topline data expected as early as Q1 2024 OCALA, Fla., Nov. 21, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the last subject has completed...
2023-11-15 13:39:04 ET AIM ImmunoTech Inc. (AIM) Q3 2023 Earnings Call Transcript November 15, 2023 08:00 AM ET Company Participants Thomas Equels - Executive Vice Chairman, Chief Executive Officer and President Christopher McAleer - Scientific Officer Conferen...
2023-11-15 07:37:48 ET More on AIM ImmunoTech Seeking Alpha’s Quant Rating on AIM ImmunoTech Historical earnings data for AIM ImmunoTech Financial information for AIM ImmunoTech For further details see: AIM ImmunoTech GAAP EPS of -$0.16 misses by $...
– Highlights continued execution across Ampligen ® clinical development programs – Company is well positioned to achieve multiple value-driving milestones during remainder of 2023 and 2024 – Will host conference call and webcast today, November 15 ...
2023-11-14 10:52:25 ET Major earnings expected before the bell on Wednesday include: JD.com ( JD ) Tencent Holdings ( OTCPK:TCEHY ) Target ( TGT ) XPeng ( XPEV ) ZIM Integrated Shipping Services ( ZIM ) For further details see: Notable ear...
OCALA, Fla., Nov. 14, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of results from the Phase 1 study at Roswell Park Comprehensive Cancer Center in patients with metastatic triple...
ABU DHABI, United Arab Emirates, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The Global Media Congress is scheduled to take place in Abu Dhabi, UAE, from November 14 to 16, 2023, following its successful 2022 edition. This year, AI-Media , will play a central role as the live caption and ...
2023-11-11 01:30:00 ET Summary Long Cast Advisers, LLC, is an independent-registered investment adviser investing on behalf of individuals, family offices and endowments. It is concentrated on long-term investing, focused on small-cap companies. Long Cast Advisors achieved cumulat...
OCALA, Fla., Nov. 09, 2023 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that management will host a conference call and webcast to discuss the Company’s Q3 2023 operational and financial r...
Data presented at the Society for Immunotherapy of Cancer (SITC) 38 th Annual Meeting Longitudinal comparison of biomarkers in tumor microenvironment showed a gradual, durable response over time in T lymphotactic CXCR3 ligands and cytolytic factors Phase 2 study ongo...
News, Short Squeeze, Breakout and More Instantly...
OCALA, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced the publication of new pre-clinical data concerning the company’s drug Ampligen as part of a combinational therapy in the...
OCALA, Fla., June 10, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Pitch Con...
OCALA, Fla., June 03, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), today announced that Thomas K. Equels, MS JD, Chief Executive Officer of AIM will participate in the Virtual Investor Lunch Break Series ...